Cumberland Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2013
Filed with the SEC on Mar 11, 2014 and accepted by EDGAR at Mar 11, 2014, 17:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-10-01 to 2013-12-31 | $8.2m | us-gaap:SalesRevenueNet |
| Cost of revenue | 12 months2013-01-01 to 2013-12-31 | $5.4m | us-gaap:CostOfGoodsSold |
| Research and development | 12 months2013-01-01 to 2013-12-31 | $5.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2013-10-01 to 2013-12-31 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2013-01-01 to 2013-12-31 | −$3.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2013-01-01 to 2013-12-31 | $103.4k | us-gaap:InterestExpense |
| Income tax | 12 months2013-01-01 to 2013-12-31 | −$1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-10-01 to 2013-12-31 | −$1.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2013-01-01 to 2013-12-31 | −$2.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-10-01 to 2013-12-31 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2013-01-01 to 2013-12-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-10-01 to 2013-12-31 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2013-01-01 to 2013-12-31 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2013-01-01 to 2013-12-31 | 18,332,997 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2013-01-01 to 2013-12-31 | $746.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2013-01-01 to 2013-12-31 | $97.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2013-01-01 to 2013-12-31 | $4.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2013-12-31 | $40.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-12-31 | $68.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2013-12-31 | $87.6m | us-gaap:Assets |
| Current liabilities | At period end2013-12-31 | $7.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-12-31 | $8.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-12-31 | $79.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001087294-14-000010. Last ingested by Listed: Nov 14, 2026, 23:39 ET. Listed shows no prices and gives no investment advice.